[go: up one dir, main page]

IL157326A0 - Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors - Google Patents

Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors

Info

Publication number
IL157326A0
IL157326A0 IL15732602A IL15732602A IL157326A0 IL 157326 A0 IL157326 A0 IL 157326A0 IL 15732602 A IL15732602 A IL 15732602A IL 15732602 A IL15732602 A IL 15732602A IL 157326 A0 IL157326 A0 IL 157326A0
Authority
IL
Israel
Prior art keywords
anticholinergics
pde
inhibitors
basis
medicament compositions
Prior art date
Application number
IL15732602A
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL157326A0 publication Critical patent/IL157326A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15732602A 2001-03-07 2002-02-26 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors IL157326A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10110772A DE10110772A1 (en) 2001-03-07 2001-03-07 New drug compositions based on anticholinergics and PDE-IV inhibitors
PCT/EP2002/001988 WO2002069945A2 (en) 2001-03-07 2002-02-26 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors

Publications (1)

Publication Number Publication Date
IL157326A0 true IL157326A0 (en) 2004-02-19

Family

ID=7676493

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15732602A IL157326A0 (en) 2001-03-07 2002-02-26 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
IL157326A IL157326A (en) 2001-03-07 2003-08-11 Pharmaceutical compositions containing tiotropium salts and pde-iv inhibitor, optionally in the form of inhalable powders, propellant-containing inhalable aerosols and inhalable solutions or suspensions comprising said compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157326A IL157326A (en) 2001-03-07 2003-08-11 Pharmaceutical compositions containing tiotropium salts and pde-iv inhibitor, optionally in the form of inhalable powders, propellant-containing inhalable aerosols and inhalable solutions or suspensions comprising said compositions

Country Status (18)

Country Link
EP (1) EP1372649B1 (en)
JP (1) JP2004521134A (en)
KR (1) KR20030081501A (en)
CN (1) CN1649588A (en)
AR (1) AR034213A1 (en)
AU (1) AU2002257587B2 (en)
BR (1) BR0207883A (en)
CA (1) CA2439763C (en)
CZ (1) CZ20032635A3 (en)
DE (1) DE10110772A1 (en)
EA (1) EA009989B1 (en)
HU (1) HUP0400782A3 (en)
IL (2) IL157326A0 (en)
MX (1) MXPA03008045A (en)
NZ (1) NZ528621A (en)
PL (1) PL363078A1 (en)
TW (1) TWI332833B (en)
WO (1) WO2002069945A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
JP2004530705A (en) * 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Combination of a PDE4 inhibitor and tiotropium or a derivative thereof for treating obstructive airway disease and other inflammatory diseases
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
DE10230769A1 (en) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug compositions based on new anticholinergics and PDE-IV inhibitors
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
US20060147382A1 (en) * 2003-03-28 2006-07-06 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
CA2519682A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
JP2007500148A (en) * 2003-07-28 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medicament containing PDEIV inhibitor and novel anticholinergic agent and use of the medicament for treating respiratory diseases
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
EP1504756A1 (en) * 2003-08-06 2005-02-09 Kyowa Hakko Kogyo Co., Ltd Medicament compositions comprising a heterocyclic compound and an anticholinergic
JP2007517820A (en) * 2004-01-09 2007-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pharmaceutical compositions based on scopine esters and nicotinamide derivatives
PL1713471T3 (en) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
SI1713473T1 (en) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
JP2007520509A (en) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Rhinitis treatment with anticholinergic drugs or in combination with antihistamines, phosphodiesterase 4 or corticosteroids
WO2005082361A1 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Roflumilast and glycopryrronium combination
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CA2595791C (en) 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
GB0521563D0 (en) 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
PL2098248T3 (en) 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids and beta2-agonists for the treatment of inflammatory diseases
HRP20110434T1 (en) 2006-08-01 2011-08-31 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2012515148A (en) 2009-01-13 2012-07-05 グラクソ グループ リミテッド Pyrimidinecarboxamide derivatives as SYK kinase inhibitors
WO2012025474A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
WO2012025473A1 (en) 2010-08-24 2012-03-01 Glaxo Group Limited Cc.chemokine receptor 4 antagonists
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102670607A (en) * 2012-05-28 2012-09-19 海南卫康制药(潜山)有限公司 Compound ambroxol hydrochloride composition and preparation method thereof
PT2968312T (en) * 2013-03-15 2018-04-19 Verona Pharma Plc Drug combination
WO2014191826A1 (en) * 2013-05-31 2014-12-04 Nexpath Medical Sa Acetabular reamer assembly

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198734A (en) * 1998-12-30 2000-07-18 Pfizer Inc Motility enhancers for the treatment of gastric motility impairment and related disorders
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
SK10342002A3 (en) * 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
US6924292B2 (en) * 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AR029984A1 (en) * 2000-07-27 2003-07-23 Smithkline Beecham Corp METHOD FOR REDUCING ASSOCIATED EXCERBATIONS COPD AMBITO

Also Published As

Publication number Publication date
HUP0400782A3 (en) 2012-09-28
IL157326A (en) 2011-12-29
PL363078A1 (en) 2004-11-15
AR034213A1 (en) 2004-02-04
KR20030081501A (en) 2003-10-17
CA2439763C (en) 2012-10-16
CN1649588A (en) 2005-08-03
HUP0400782A2 (en) 2004-07-28
EA009989B1 (en) 2008-04-28
EP1372649A2 (en) 2004-01-02
EA200300929A1 (en) 2004-04-29
MXPA03008045A (en) 2003-12-04
JP2004521134A (en) 2004-07-15
DE10110772A1 (en) 2002-09-12
TWI332833B (en) 2010-11-11
EP1372649B1 (en) 2012-07-25
NZ528621A (en) 2005-04-29
WO2002069945A3 (en) 2003-01-30
CZ20032635A3 (en) 2004-09-15
AU2002257587B2 (en) 2007-05-10
BR0207883A (en) 2004-07-27
WO2002069945A2 (en) 2002-09-12
CA2439763A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
IL157326A0 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
EP1383743A4 (en) Dual inhibitors of pde 7 and pde 4
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
IL158076A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
IL158523A0 (en) Epothilone derivatives and pharmaceutical compositions containing the same
PL372620A1 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
HUP0500173A3 (en) Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2002338806A1 (en) Pharmaceutical combinations of pde-v inhibitors and other agents
IL156759A0 (en) Kits and pharmaceutical compositions containing epothilone derivatives
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
HUP0303193A3 (en) Phthalayinone-piperidino-derivatives as pde4 inhibitors and pharmaceutical compositions containing them
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
IL165775A0 (en) Novel quinuclidine derivatives and medicinal compositions containing the same
ZA200306082B (en) Parasiticidal compositions and methods of use
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2003233445A1 (en) Antimicrobial compositions and methods of use
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
HUP0402537A3 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors